ArticleVaccine2021

Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.

DeAnna J Friedman-Klabanoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.